Get the Stockscreener App
1.705
3.12%
-0.055
Innate Pharma Adr stock is traded at $1.705, with a volume of 13,632.
It is down -3.12% in the last 24 hours and down -22.68% over the past month.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
See More
Previous Close:
$1.76
Open:
$1.723243
24h Volume:
13,632
Relative Volume:
0.09
Market Cap:
$190.45M
Revenue:
$3.13M
Net Income/Loss:
$-55.77M
P/E Ratio:
-2.7746
EPS:
-0.6145
Net Cash Flow:
$-61.24M
1W Performance:
-10.73%
1M Performance:
-22.68%
6M Performance:
+35.32%
1Y Performance:
-7.34%
1-Day Range:
$1.70
$1.73
1-Week Range:
$1.70
$1.94
52-Week Range:
$1.17
$2.71
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.705 | 196.59M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
521.91 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
792.79 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
184.30 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
953.24 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.41 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Sep-18-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-18-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-28-25 | Initiated | BTIG Research | Buy |
| Sep-03-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-15-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-24-20 | Initiated | Goldman | Neutral |
View All
Innate Pharma Adr Stock (IPHA) Latest News
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Innate Pharma stock maintained at Buy by H.C. Wainwright - Investing.com
Innate Pharma Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip - Investing.com India
Innate Pharma, Grove, and more set to report earnings Thursday - Investing.com
Innate Pharma closes Sobi partnership, receives $75m upfront - Investing.com
Innate Pharma at H.C. Wainwright conference: narrower pipeline, bigger bets By Investing.com - Investing.com India
Innate Pharma S.A. ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - sharewise.com
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
FY2026 EPS Estimates for Innate Pharma Reduced by Analyst - MarketBeat
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com South Africa
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com India
Innate Pharma partners with Sobi on lacutamab development - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer - Investing.com
Innate Pharma (IPHA) Holds Steady at $1.68 as Consolidation Pattern DeepensVWAP Bounce - vinanet.vn
Innate Pharma completes enrollment in IPH4502 phase 1 study - Investing.com
Innate Pharma completes enrollment in IPH4502 phase 1 study By Investing.com - Investing.com South Africa
IPHA Q1 2026 Earnings: Significant EPS Miss on R&D InvestmentsEPS Surprise History - po-news-eg.net
Form 13G Innate Pharma SA For: 22 June By Investing.com - Investing.com South Africa
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
IPHAInnate Pharma ADR Stock Price and Quote - Finviz
AUTL - Finviz
IPHA Technical Analysis | Trend, Signals & Chart Patterns | INNATE PHARMA SA-SPONS ADR (NASDAQ:IPHA) - ChartMill
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Innate Pharma Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts - Investing.com
Unusual VolumeStock ScreenerNews - Finviz
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Top GainersStock ScreenerSnapshot - Finviz
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - marketbeat.com
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
NASDAQ New 52-Week Highs And Lows - Moomoo
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - investing.com
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Adr Stock (IPHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):